🔗 Share this article World Health Organization Issues Alert Over Severe Shortage of Weight-Loss Medications Under one in 10 individuals who could benefit from GLP-1 drugs such as Wegovy can access them, warns the World Health Organization as it releases its inaugural advice on the medications. With more than one billion individuals worldwide currently living with obesity, it is calling for increased and just availability to GLP-1 medication. Per forecasts, in excess of 2,000,000,000 will be obese by 2030 without intervention. "The latest guidelines recognises that excess weight is a long-term condition that can be treated with holistic and lifelong treatment," stated the agency's head Tedros Adhanom Ghebreyesus. Substantial prices, insufficient output, and logistical bottlenecks are significant barriers to widespread availability to the injections that can assist patients in reducing significant body mass, notes the organization. Skinny Jab Scarcity Despite the present most favorable case, the production of GLP-1 therapies could only cover around 100 million people – fewer than 10% of those who need them, as stated by the WHO. The recommendation calls on nations and manufacturers to increase access, by measures including voluntary licensing. Exclusive production rights on a key compound – the core component of a leading brand – is set to lapse in a number of countries in 2026. How Obesity Injections Function The injections replicate a natural hormone to slow digestion, suppress the appetite and boost the sense of being full so individuals reduce food intake. Individuals usually start to lose weight in the initial weeks of commencing the regular doses. Studies suggests people may put most of the weight back on after a year of stopping the drug, when their usual appetite come back. To be overweight or obese increases your likelihood for experiencing medical conditions, such as diabetes, heart disease, stroke, and certain cancers. Obesity affects individuals in all nations and was associated with 3.7 million deaths worldwide in 2024, per the health agency.
Under one in 10 individuals who could benefit from GLP-1 drugs such as Wegovy can access them, warns the World Health Organization as it releases its inaugural advice on the medications. With more than one billion individuals worldwide currently living with obesity, it is calling for increased and just availability to GLP-1 medication. Per forecasts, in excess of 2,000,000,000 will be obese by 2030 without intervention. "The latest guidelines recognises that excess weight is a long-term condition that can be treated with holistic and lifelong treatment," stated the agency's head Tedros Adhanom Ghebreyesus. Substantial prices, insufficient output, and logistical bottlenecks are significant barriers to widespread availability to the injections that can assist patients in reducing significant body mass, notes the organization. Skinny Jab Scarcity Despite the present most favorable case, the production of GLP-1 therapies could only cover around 100 million people – fewer than 10% of those who need them, as stated by the WHO. The recommendation calls on nations and manufacturers to increase access, by measures including voluntary licensing. Exclusive production rights on a key compound – the core component of a leading brand – is set to lapse in a number of countries in 2026. How Obesity Injections Function The injections replicate a natural hormone to slow digestion, suppress the appetite and boost the sense of being full so individuals reduce food intake. Individuals usually start to lose weight in the initial weeks of commencing the regular doses. Studies suggests people may put most of the weight back on after a year of stopping the drug, when their usual appetite come back. To be overweight or obese increases your likelihood for experiencing medical conditions, such as diabetes, heart disease, stroke, and certain cancers. Obesity affects individuals in all nations and was associated with 3.7 million deaths worldwide in 2024, per the health agency.